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Relatively little is known about how drug self-association influences absorption into the human body.
This study presented two hydrophobic membranes with a series of solutions containing different types
of tetracaine aggregates with the aim of understanding how the attributes of supramolecular aggregate
formation influenced passive membrane transport. The data showed that aqueous solutions of the unpro-
tonated form of tetracaine displayed a significantly higher (p < 0.05) passive membrane transport com-
pared to solutions with mixtures of the unprotonated and protonated drug microspecies (e.g. transport
through the skin was 0.96 ± 0.31 lg cm2 min1 and 1.59 ± 0.26 lg cm2 min1 respectively). However,
despite an enhanced rate of drug transport and a better membrane partitioning the unionised molecules
showed a significantly longer (p < 0.05) lag time to membrane penetration compared solutions rich in the
ionised microspecies. Analytical characterisation of the solutions applied to the apical surface of the
membranes in the transport studies showed that larger tetracaine aggregates with smaller surface charge
gave rise to the longer lag times. These large aggregates demonstrated more extensive intermolecular
bonding and therefore, it was suggest that it was the enhanced propensity of the unionised species to
form tightly bound drug aggregates that caused the delay in the membrane penetration.
 2016 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Pharmacologically active compounds can display amphiphilic
properties and this can lead to molecular aggregation in solution.
Aggregate formation can have a significant impact on the biological
function of a molecule because it can influence the passage
through membranes. These changes are driven by alterations in
diffusion speed and modification of the interactions with other
molecules [1–3]. However, the physical interactions between the
aggregated and non-aggregated entities, the multiple routes that
molecules can take through a barrier and the potential for both
the unaggregated and aggregated drug to pass through a mem-
brane mean that the influence of molecular aggregation upon
transport is a complex field of study that warrants further
investigation.
One example of a molecule that is known to aggregate in solu-
tion is tetracaine [4]. Its self-association is thought to be driven by
intermolecular tertiary amine hydrogen bonding and amine–ester
hydrogen bonding [4]. Tetracaine has a good bioavailability whenapplied topically to biological membranes [5–7], but it can have
a slow onset of topical anaesthesia (30–60 min), which hinders
its effective clinical use in certain contexts [8–10]. Attempts to
enhance tetracaine diffusion across the membranes have been
reported in the literature [11–13], but there has been very little
investigation into how molecular aggregation influences the
passive diffusion of this drug and thus the consequences of molec-
ular aggregation on its speed of onset remain unknown.
Tetracaine is commercially available as a 4% gel (formulation
pH  9) and can exist in solution as three different microspecies
depending on the pH. Tetracaine base (TC) is thought to be the effi-
cient in crossing biological barriers [14], and it is the dominant
microspecies above pH 9. Below pH 6.5 both the tertiary (TCH+)
and secondary amine (TCH22+) are protonated and the microspecies
TCH+ prevails at the physiological pH of the skin (4.2–6.5). It is
generally accepted that the tetracaine tertiary amine binds to the
sodium channels, blocking the sodium influx, inhibiting nerve cell
depolarization and preventing the propagation of nerve cell
impulses [15], but which is the most effective species to gain rapid
penetration into the skin remains less clear.
The aim of this work was to use tetracaine as a model drug in
order to gain a better understanding of how the physical attributes
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tion influence hydrophobic membrane transport. Tetracaine was
chosen as the model agent due to the fact that its amphiphilic char-
acteristics could be manipulated by simply altering the pH of aque-
ous solutions containing the drug when it was above its critical
aggregation concentration (CAC). This allowed a series of aqueous
vehicles where the degree of ionization of both the tertiary and
secondary amine was varied to be presented to two hydrophobic
membranes, porcine skin and silicone, in the anticipation that differ-
ent types of drug aggregates and different transport rates could be
recorded andanalysed. Skinwas chosen as an example of a biological
barrier as there was evidence in the literature that tetracaine could
pass through thismembrane [5–7]. Photon correlation spectroscopy
was employed to determine the critical aggregation concentration at
which nanosized aggregates were formed and zeta potential
measurements provided details of the electrostatic interactions.
Fourier transform infrared spectroscopy (FTIR) and 1H NMR were
employed to investigate themolecular arrangement and intermolec-
ular bonding between the different microspecies in solution.
2. Materials and methods
2.1. Materials
Acetonitrile and methanol both HPLC grade, grade A glass pip-
ettes, clear glass high performance liquid chromatography (HPLC)
vials with crimpable lids and 0.45 lm nylon filter papers were pur-
chased from Fischer Scientific (Leicester, UK). Tetracaine base BP
grade (99.9%) and deuterium oxide (99.9 atom%) were supplied
by Sigma Aldrich (Dorset, UK). Concentrated hydrochloric acid
and sodium hydroxide were from Fluka (Dorset, UK). Sodium acet-
ate, potassium dihydrogen phosphate and 1-Octanol were provided
by Alfa Aesar (Heysham, UK). Silicone membranes with a thickness
of 0.25 mm were purchased from GBUK Healthcare (Selby, UK).
2.2. Tetracaine pKa determination
The automatic titration system used in this study comprises an
autoburette (Dosimat 765 liter ml syringe, Metrohm, Buckingham,
UK) and pH meter (MP230 Mettler Toledo, Leicester, UK) with a pH
electrode (Metrohm, Buckingham, UK). A 0.1 M KCl electrolyte
solution was used to maintain the ionic strength. The temperature
of the test solutions was maintained in a thermostatic jacketed
titration vessel at 25 C ± 0.1 C by using a temperature controller
(Techne TE-8J, Sigma–Aldrich, Dorset, UK). The solution under
investigation was stirred vigorously during the experiment. A
pump with speed capability of 20 mL min1 (Mini-plus, Gilson,
Luton, UK) was used to circulate the test solution through a quartz
flow cuvette using a cuvette with a path length of 0.1 cm. The flow
cuvette was mounted on an UV–visible spectrophotometer (HP
8453, Agilent, Cheadle, UK). All instruments were interfaced to a
computer and controlled by a Visual Basic program. Automatic
titration and spectral scans adopted the following strategy: the
pH of a solution was increased by 0.1 pH unit by the addition of
KOH from the autoburette; when pH readings varied by <0.001
pH unit over a 3 s period the spectrum of the solution was then
recorded. The cycle was repeated automatically until the defined
end point pH value was achieved. All the titration data were
analysed with the pHab program [16]. The microspecies plot was
generated with the HYSS program [17].
2.3. Tetracaine aggregate analysis
2.3.1. Photon correlation spectroscopy characterisation
Changes in derived count rate and zeta potential of the donor
solutions were tracked using photon correlation spectroscopy(PCS) (Malvern Nanoseries Zetasizer, Malvern Instruments Ltd.,
Malvern, UK). Measurements were taken at a scattering angle of
173. Refractive index and viscosity constants were set at 1.33
and 0.88 mPa s, respectively. Samples were filtered through a
0.45 lm cellulose nitrate filter prior to the analysis. The scattering
information was determined at increasing tetracaine molar con-
centrations in acetate buffer (0.1 M) at pH 4, 6, 7.6, 9 and 10. The
critical aggregation concentration was determined from the data
discontinuity in the linear model applied to the derived count rate
data; this was confirmed by the application of a second derivative
function (OriginPro 9.1 Software, OriginLab, Northampton, USA).
The size of the molecular aggregates was detected by converting
the signal into a hydrodynamic radius using the Stokes–Einstein
equation given in (Eq. (1)), where k is the Boltzmann constant, T
is the absolute temperature and g is the solvent viscosity. The size
of the molecular aggregates was determined above critical aggre-
gation concentration ca. 87–95% of tetracaine saturation in each
aqueous vehicle at pH 4, 6, 7.6, 9 and 10. The pH was adjusted to
the required value when necessary by adding NaOH (1 M) or acetic
acid. Zeta potential magnitude was determined at pH 4, 7.6 and 9
using the same solutions described above.
RH ¼ kT6pgD ð1Þ2.3.2. Molecular dynamic studies
Tetracaine self-assembly was generated from the crystal struc-
ture reported by Nowell et al. [18]. The atomic co-ordinates and
unit cell parameters were obtained from the Cambridge Structural
Database; entry XISVOK [19]. The assembly was generated
(2  2  2 unit cells) using the Mercury software [20] and then
visualised using Accelrys Viewerlite v5.0 (Biovia, San Diego, USA).
2.3.3. Apparent distribution coefficient
The apparent drug distribution coefficients were measured
using tetracaine saturated solutions at room temperature as previ-
ously described, using n-octanol in acetate buffer (0.1 M) at pH 4,
6, 7.6, 9 and 10 [21]. After phase separation the aqueous phase
was withdrawn and samples were centrifuged at 13,000 rpm
(Biofuge, Heraeus, Germany) and aliquots of the liquid phase were
then transferred into vials. The samples were analysed using HPLC.
The apparent distribution coefficient (D) was defined as the ratio of
the drug concentration in octanol (C0) to the total concentration of
ionised (Ci) and unionised (Cu) drug in the aqueous phase (Eq. (2)).
D ¼ C0ðCi þ CuÞw ð2Þ2.3.4. Fourier transform infrared spectroscopy (FTIR) characterisation
Tetracaine solutions at pH 4, 6, 7.6, 9 and 10 were prepared in
deuterium oxide at the same concentrations used for molecular
aggregate size analysis. Deuterium oxide (D2O) was employed in
the solutions as it dampened the solvent signal in the 1700–
1300 cm1 range. The pH was adjusted with NaOH (1 M) or acetic
acid. The samples were loaded into a demountable universal trans-
mission cell system (Omni-Cell, Specac Ltd., Kent, UK) fitted with
CaF2 windows and a 25 lm mylar spacer (Specac Ltd., Kent, UK).
The infrared spectra were recorded from 4500 to 1000 cm1 using
a Spectrum One spectrometer (Perkin Elmer Ltd., Bucks, UK) and
spectral analysis was performed with Spectrum software version
5.3.1 (Perkin Elmer Ltd., Bucks, UK). After normalisation of trans-
mittance, background subtraction and baseline correction of the
spectra, hydrogen bonding interactions in the carbonyl group
region were determined by analysing spectral shifts of the C@O
stretching peak as described previously [22].
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Tetracaine solutions at pH 4, 6, 7.6, 9 and 10 were prepared in
deuterium oxide at the same concentrations used for molecular
aggregate size analysis. The spectra of each solution were obtained
with a Bruker Avance DRX400 NMR spectrometer (Bruker, Coven-
try, UK). A 600 lL aliquot of each sample was used for the mea-
surements which were conducted at 400 MHz with 5000 scans.
The peak assignments in the spectra were made and supported
using the predicted spectra (ChemNMR software, Perkin Elmer,
Beaconsfield, UK).
2.4. Transport studies
To eliminate any thermodynamic influence on the drug passive
transport across both membranes, tetracaine was formulated as a
saturated solution i.e. at a thermodynamic activity of unity [23,24].
Using a fine suspension to produce the saturated solutions allowed
visual inspection to confirm saturated conditions were maintained
throughout the experiments. The individually saturated solutions
at pH 4, 6, 7.6, 9 and 10 were prepared by adding excess tetracaine
to acetate buffer (0.1 M). The pH of each solution was adjusted to
the required value when necessary by adding NaOH (0.1 M).
Adult pig ears were obtained from a local abattoir. The ears
were removed from the carcass after hair removal. Any ears that
were obviously damaged were discarded. The ears were cleaned
with water, the residual water on the skin surface was immedi-
ately removed by blotting with tissue, visible residual hairs were
trimmed carefully and the ears were stored at 20 C (no more
than three months before using). Porcine skin was defrosted and
the subcutaneous fat carefully removed using a scalpel. Both the
silicone membrane (0.25 mm thick, used as obtained) and the por-
cine skin were cut into pieces of a suitable size and mounted in the
Franz diffusion cell (University of Southampton, UK) [25] with sur-
face areas of approximately 2 ± 0.2 cm2 and receiver compartment
volumes of approximately 9.5 mL. Porcine skin was mounted with
the stratum corneum facing the donor compartment. The receptor
compartment of the cells was filled with acetate or phosphate buf-
fer (0.1 M) at the same pH as the donor compartment. To ensure
there was no leakage, the cells were inverted and visually checked.
Leaking cells were excluded from the experiments. In order to
guarantee uniform mixing of the receptor phase and maintenance
of sink conditions (drug concentration in the receiver fluid did not
exceed 10% of its saturated solubility), 13 mm magnetic stirrer
fleas were placed in the receptor compartment of the Franz cells.
Five cells were used for each experiment and they were allowed
to equilibrate for 30 min prior to use by immersing the receptor
compartments in a 37 C water bath (Grant instruments, Cam-
bridge, UK). A 3 mL sample of each saturated solution was applied
to the apical surface of the membrane to initiate the transport
studies. At specified time intervals over a period of 6 h and 22 h
(for the silicone and porcine membrane respectively), 1 mL sam-
ples were taken out of sampling arm of the receiver compartment
and immediately replaced by fresh acetate buffer of equal volume
and temperature. Samples were stored at room temperature until
HPLC analysis was carried out. Cumulative amounts of drug (lg)
penetrating the membrane per unit diffusional surface area (cm2)
were corrected for previous sample removal and plotted against
time (min). The linear region of the plot (R2 > 0.99 over at least 5
points) was defined as the steady-state flux. Membrane thickness
was measured before and after the transport experiments using a
Vernier micrometer (No. 436.1 Series 0–25 mm) purchased from
Starrett (Jedburgh, UK), in order to check for swelling which would
indicate vehicle–matrix interaction [26]. Lag time was determined
by the intercept of the line extrapolated from the linear model
applied to the data in order to calculate steady-state flux with
the x axis and it was provided in min.2.5. Tetracaine HPLC assay
A liquid chromatography pump (P680 HPLC pump, Dionex, Sur-
rey, UK) with an ASI-100 automated sample injector (Dionex, Sur-
rey, UK) connected to a PDA-100 photodiode array detector
(Dionex, Surrey, UK), was used for the quantitative determination
of tetracaine. The HPLC system was connected to a computer with
a Chromeleon software (Dionex, Surrey, UK), which was used to
record and analyse the chromatograms. A Luna C18 (5 lm,
250  4.6 mm) column (Phenomenex, Cheshire, UK) was used with
a 50:25:25 acetate buffer (0.1 M)/methanol/acetonitrile mobile
phase at pH 4 and a flow rate of 1 mL min1. Volumes of 50 lL
were injected onto the column and tetracaine was analysed at a
wavelength of 311 nm. The method was previously shown to be
fit for purpose in terms of linearity (R2 > 0.999), peak symmetry
(0.8–1.3) and sensitivity (the limit of detection was 3.3 lg mL1
and the limit of quantification was 9.7 lg mL1) in accordance
with the limits described by the International Conference on
Harmonisation guidelines [27]. The tetracaine retention time was
7.62 min. The liquid chromatography method was found to be
stability indicating and was able to detect tetracaine hydrolytic
degradation products p-n-butylaminobenzoic acid and diethy-
laminoethanol [28].
2.6. Statistical data analysis
Statistical evaluation was carried out using a statistical package
for social sciences software (SPSS version 11.0, SPSS Inc., Chicago,
IL, USA). The Kolmogorov–Smirnov test was used to check the nor-
mality of the data. Data were analysed by one-way ANOVA and
post hoc comparisons of the means of individual groups were
performed using Tukey’s Honestly Significant Difference test. In
all cases, a statistically significant difference was defined as when
p 6 0.05. All values were expressed as mean ± standard deviation.
The number of replicates was 5 in the permeation studies and 3
in the apparent distribution coefficient determination and light
scattering studies.3. Results and discussion
3.1. Tetracaine pKa determination
The analysis of the titration data using the pHab program
revealed two inflection points at pH values of 2.48 ± 0.03 and
8.56 ± 0.02 in the plots of tetracaine solution UV absorbance versus
its pH and these were considered to be the approximate values of
tetracaine pKa’s (Fig. 1). The pKa value at 2.48 ± 0.03 was assigned
to the protonation on nitrogen of the tertiary amine and the pKa
value of 8.56 ± 0.02 was assigned to the secondary amine. There
was a good agreement between the experimentally determined
values in this work and those described in the literature. For exam-
ple, Iglesias et al., (2012) reported a tetracaine pKa value of 3.41
and 8.24 [15]. Therefore, the percentage of each microspecies in
solution (TC, TCH+ and TCH22+) at increasing pH was calculated
using the experimentally determined pKa’s from this work
(Table S1, Supplementary data). The commercial topical product
displayed an apparent pH of ca. 9 and therefore it was considered
to present tetracaine predominantly as a unionised molecule (TC)
when it was used clinically to induce topical anaesthesia.
3.2. Tetracaine supramolecular aggregate analysis
3.2.1. Photon correlation spectroscopy characterisation
The critical aggregation concentration of the drug solutions was
significantly higher (p < 0.05) when they contained species with
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Fig. 1. UV-spectrum of tetracaine (560 lM) between pH 2.36 and pH 10.94 starting
in 20.1 mL of KCL (0.1 M) at 25 C using a cuvette with a path length of 0.1 cm. Total
points represented are 44.
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nes, i.e. the critical aggregation concentration was 18 ± 1.4 mM
(Fig. 2) at pH 4 and 3 ± 0.9 mM at pH 7.6 compared to
0.7 ± 0.1 mM at pH 9 and 0.5 ± 0.1 mM at pH 10. The two CAC val-
ues recorded at pH 9 and 10 were not significantly different
(p > 0.05). This trend in the data indicated that the self-
association process was more favourable when the unionised
tetracaine microspecies were prevalent in aqueous solutions (for
additional information see Fig. S1 and Table S1 included in the
Supplementary data). The 4% (w/w) tetracaine commercial gel
presented the molecule to the skin as a two phase system, and
microscopy analysis showed that it contained drug microcrystals
(Fig. 3a and b). In addition, the CAC data indicated the active mole-
cules in the bulk solution of this formulation were probably in both
aggregated and unaggregated states. Together these physical data
demonstrated that the commercial system was a complex delivery
system.
The relatively high polydispersity index (P0.25) measured for
all test systems indicated that there were different sized aggre-
gates in solution and this suggested that the aggregates did not
form a highly ordered structure such as a micelle (Fig. 4b–d). The
size of the aggregates present in solution above the tetracaine
CAC was shown to be significantly greater (p < 0.05) when the pro-Fig. 2. Graph depicting the changes in total light scattering for samples at pH 4. Inset gr
discontinuity in the slope of the derived count rate data. Critical aggregation concentrati
significant difference between CAC results (Tukey’s Honestly Significant Difference test)portion of charged species in solution was reduced, i.e., the average
aggregate size was 114 ± 8.3 nm at pH 4 whilst it was
188 ± 20.4 nm at pH 9 (Fig. 4a). The zeta potential of the solutions
containing more of the charged amine species was also signifi-
cantly higher (p < 0.05) (4.34 ± 1.8 mV at pH 4 vs 0.98 ± 0.2 mV at
pH 9). The zeta potential data suggested that the supramolecular
structures formed from the ionised tetracaine microspecies were
influencing the surface charge of the aggregate. Molecular
modelling of the tetracaine aggregate structure using the crystallo-
graphic data supported this hypothesis. When tetracaine forms
crystals the charged amine is most likely to orientate towards
the surface of the structure rather than the interior, and if this also
occurred in the liquid state then this would be the reason why the
aggregate charge was altered by the proportion of ionised species
in solution (Fig. 5). Whilst it is accepted that the supramolecular
formation in solution is not the same process as supramolecular
structure formation during crystallisation this explanation
provides a hypothesis for further studies to test.3.2.2. Tetracaine partitioning
The experimentally determined LogD values of tetracaine donor
solutions at pH 4.0, 6.0, 7.6, 9 and 10 showed the same trend as the
calculated values (Fig. 6). The most significant differences were
surprisingly at the higher pH’s of 9 and 10 where the experimental
distribution coefficients were recorded as 2.1 ± 0.16 and
2.01 ± 0.18 respectively. As the amount of tetracaine detected in
the aqueous phase of the partitioning experiments was above the
experimentally determined critical aggregation concentration for
all test systems it was assumed that the differences in the pre-
dicted and measured values were a consequence of supramolecular
tetracaine structures. As the experimental partition coefficient was
lower than the predicted value this indicated that molecular aggre-
gates were in fact more hydrophilic than the unaggregated tetra-
caine. This was a surprising result, but it was possible that the
aggregates did contain a component of the ionised amine even at
pH 9 and 10, and if, as the molecular simulation images suggest,
these are orientated more preferably towards the surface of the
aggregate it is possible that these ionised species increased the
hydrophilicity of aggregates compared to the unaggregated mole-
cules that were assumed to exist in the calcaulated values.3.2.3. Fourier transform infrared spectroscopy
The FTIR spectra of tetracaine at pH 4 were characterised by the
presence of the C@O group (1707 cm1) and two vibrational bandspH CAC 
4 18 ± 1.4 
6    25 ± 4.1 * 
7.6    3.1 ± 0.9 * 
9    0.7 ± 0.1 * 
10 0.5 ± 0.1 
aph represents the application of a second derivative function that determined the
on (CAC) values for each test system are displayed in the table. ⁄p < 0.05 represents
. Each point represents mean ± standard deviation (n = 3).
(b)(a)
Fig. 3. Light microscopy (Olympus BX50F, Japan) at a magnification of 40 (a) tetracaine commercial product and (b) tetracaine test system at pH 9 above critical aggregation
concentration.
Fig. 4. Graph depicting the changes in (a) molecular aggregates size (nm) at increasing pH of the donor solution and size distribution above critical aggregation concentration,
(b) at pH 4, (c) at pH 7.6 and (d) at pH 9. Each point represents mean ± standard deviation (n = 3).
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absorption frequency (Fig. 7). The hydroxyl bands were thought to
arise due to the intermolecular interactions of tetracaine in solu-
tion [29,30]. Similar effects have previously been observed with
other drug–drug interactions in solution [31]. Above pH 4, the
stretching vibrational band assigned to the C@O group was no
longer present (Fig. 7, data at pH 6 and 10 are not shown for
greater visual clarity), and there was a significant upfield shiftand broadening of the vibrational bands assigned to the hydroxyl
group (e.g. 1473 cm1 at pH 9). This suggested that there was an
increasingly favourable environment for aggregation driven by
stronger intermolecular interactions in the solutions at a higher
pH. The FTIR data suggested that the tetracaine molecules respon-
sible for the supramolecular structure formation utilised hydrogen
bonds formed through an NAHAO@C association. It was still con-
sidered a possibility that NAHANAH association could play a role
Fig. 5. Screenshot of a 16 molecule tetracaineHCl self-assembly generated from the
crystal structure using the Mercury software and visualised using Accelrys
Viewerlite v5.0. Atom colour scheme: H = white, C = grey, O = red, N = blue,
Cl = green. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
Fig. 6. Experimental and calculated distribution coefficient values for tetracaine at
different pHs. Each point represents mean ± standard deviation for the experimen-
tal data (n = 5).
C-O-H C=O 
Fig. 7. Fourier transform infrared (FTIR) transmittance spectra (arbitrary units) of
the C@O band of tetracaine in deuterium oxide at pH 4, 7.6 and 9 above the
experimentally determined critical aggregation concentration.
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Fig. 8. 1H NMR spectra of tetracaine in deuterium oxide, (a) pH 4, (b) pH 6, (c) pH
7.6, (d) pH 9 and (e) pH 10 in a concentration above the experimentally determined
critical aggregation concentration.
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amines in water were very weak it was impossible to arrive at firm
conclusions with regard to the amine involvement in the tetra-
caine–tetracaine association.
3.2.4. 1H NMR spectroscopy studies
There were 9 protons that gave clearly resolved peaks in NMR
spectra (Fig. 8, Table S2). The resonance of the methylene protons
H1, H2, H3 of the alkyl chain of the secondary amine and the
methyl group (H9) attached to the tertiary amine remained essen-
tially unchanged regardless of the pH environment of tetracaine.
However, the chemical shift of all the other protons tended to
move downfield (deshielding effect) with an increasing pH. The
methylene protons of the alkyl chain adjacent to the oxygen of
the ester group (H7) displayed the largest frequency change of
1.16 ppm as the pH increased from 4 to 10. In addition, the H7
proton changed in its multiplicity appearing as a quartet at pH 9.
The other significant proton chemical shift change was the methy-
lene adjacent to the tertiary amine (H8) which moved 0.4 ppm as
the pH increased from 4 to 10. The chemical shifts of the aromaticprotons attached to the benzene ring and the methylene protons
adjacent to the secondary amine changed by relatively small
amounts, but there was a change in the multiplicity of these pro-
tons at pH 10.
Fig. 9. Tetracaine transport profile through (a) silicone membrane using an infinite
dose of aggregated drug at pH 4, pH 6, pH 7.6, pH 9 and pH 10 and through (b)
porcine skin using an infinite dose of aggregated drug at pH 4, pH 7.6 and pH 9. The
inset graph represents lag time versus pH. Each point represents mean ± standard
deviation (n = 5). ⁄p < 0.05 (one-way ANOVA with Tukey’s HSD test).
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increased could indicate a possible change in the free movement
of the tetracaine molecules in solution, suggesting that the rotation
of the methylene protons of the lateral alkyl chains was inhibited
by intermolecular bonding between tetracaine molecules [32]. This
increasing steric hindrance, which increased with pH, indicated, in
a similar manner to the FTIR data, that when more of the non-
ionised tetracaine molecules were present in solution a more
tightly bound supramolecular structured was formed. Previous
studies on the interactions of model polyamines in supramolecular
structures have shown similar results [33,34].
3.3. Tetracaine transport studies
Two membranes were used in this work, a synthetic silicone
membrane, which presents a homogeneous non-porous barrier to
diffusion, and porcine skin, which is the typical in vivo preclinical
model used to characterise topically applied medical products
(due to its similar permeability and histological characteristics to
human skin [35,36]). Porcine skin allows molecules to pass
through its barrier both via the confluent structure presented by
the cells in the various skin layers and the pores introduced into
the skin structure via hair follicles and sweat glands. In contrast,
the synthetic silicone membrane only allows transport through
its barrier via the classical partitioning and diffusion process which
has been modelled by Higuchi [37]. By combining the data from a
series of test systems using both membranes it was hoped that an
understanding of how the molecules passed through the barriers
could be obtained.
The data confirmed that at each pH the synthetic membrane
(Fig. 9a) and porcine skin (Fig. 9b) were acting as rate limiting bar-
riers. The experiments applied an infinite dose of the drug that was
saturated in an aqueous solution which was thought not to interact
with the membrane. A calculation of the total drug transport
through the membrane in each experiment suggested that no drug
depletion took place and hence it was assumed that tetracaine was
constantly supplied in the transport studies at unity to the barrier.
Sink conditions in the receiver compartment were maintained for
each experiment, i.e., tetracaine concentration in the receiver fluid
did not exceed 10% of the saturated solubility at each experimental
pH [38]. Therefore, it was assumed that the cumulative rate of drug
passing the membrane taken from the exponential portion of the
cumulative drug concentration vs time plots could be considered
to be the steady-state flux.
The transport data showed in general that the drug flux and
penetration lag time increased as the solution pH of the donor
solutions was increased (Tables S3 and S4). This increase in drug
flux was thought to be a consequence of the increase in the per-
centage of unionised tetracaine in the donor solution, which had
a greater affinity for the membrane. This hypothesis was built from
the distribution data and the fact that this trend was shown in both
membranes suggested that the main mechanism of transport was
passive diffusion through the confluent barrier presented by the
cells of the skin rather than transport via the follicular route
(Fig. 9).
Traditionally, when the transport of a non-aggregated drug
system increases the membrane penetration lag time decreases.
However, in the present study the lag time increased. For example,
when the unionised fraction increased in the donor solution
increased from 0.03% to 73.4% (pH 4 and pH 9 respectively) there
was a significant increase (p < 0.05) in lag time from 3.1 ± 0.8 min
to 14 ± 1.1 min and from 123 ± 3.9 to 243 ± 10.9 min using the syn-
thetic membrane and porcine skin respectively (Tables S3 and S4).
These data were thought to be a consequence of the supramolecu-
lar structuring of tetracaine having a significant functional effect
on the drug transport kinetics. The two most likely causes of theincreases in lag time were considered to be specific interactions
between the drug and the barrier and the different availabilities
of membrane transportable species in the donor solutions [39].
However, as the aggregate characterisation data had already
shown that larger, more tightly formed drug supramolecular com-
plexes were formed at high pH’s it was thought that the greater
restriction of the rapidly diffusing unionised microspecies of tetra-
caine by the large hydrophobic masses, which may themselves
have difficulty in passing through or leaving the barrier, was the
main cause of the general trend of an increased lag time as pH of
the donor solutions increased [40].
There was an interesting exception in the general trend of an
increase in membrane penetration lag time as the donor solution
pH was increased, i.e., when tetracaine showed the lowest penetra-
tion lag time at pH 7.6 through the synthetic membrane. This effect
was not mirrored in the porcine skin. However, as the light scatter-
ing data, the partitioning data and the NMR data did not show any-
thing particular in the tetracaine solutions at pH 7.6 and the reason
for this effect could not be derived from the current data set. It was
assumed that at pH 7.6 the self-assembled structure of tetracaine
was generated in such a manner that it provided optimal condi-
tions for the tetracaine to pass through the silicone membrane.
There was a discrepancy in the skin and silicone membrane data
regarding the ability of tetracaine to pass the barrier when pre-
sented in aqueous solutions adjusted to pH 7.6. This suggested that
R. Inacio et al. / European Journal of Pharmaceutics and Biopharmaceutics 102 (2016) 214–222 221the different microspecies did take different routes through the
skin at this pH and it accords with previous work, which has shown
that ionic drug aggregates have the potential to pass the skin via as
the transappendageal route [41]. It was thought to be problematic
to study the transappendageal route for this molecule as tagging
the drug with a marker to allow tracking through the skin would
change its properties. However, this was not thought to signifi-
cantly detract from the study results because despite the multiple
routes of transport available for tetracaine and the possible
involvement of the transappendial route at pH 7.6, passive trans-
membrane transport was still considered to be the dominant mode
of barrier penetration for this molecule. This is why the drug aggre-
gation, which presented the membrane with large supramolecular
structures that needed to dissociate to provide free drug to pene-
trate the membrane, increased the lag-time of the transmembrane
transport process [42–44].
4. Conclusions
The data from the current study demonstrated that the aggrega-
tion process of tetracaine molecules was more favourable in the
aqueous vehicles at pH 7.6, 9 and 10 and this resulted in different
supramolecular structures to be formed in solution when com-
pared to the aqueous vehicles at pH 4 and 6. The type of
supramolecular structure produced in solution seemed to have
an influence on transmembrane penetration when applied to both
porcine skin and a silicone membrane. Unionised tetracaine mole-
cules had a higher affinity with the hydrophobic membranes and
this generated the highest flux values but the process of transport
was initially retarded by the aggregate formation. Spectroscopic
analysis of the aggregates showed that the unionised microspecies
promoted the formation of larger hydrophobic structures and it
was the production of these structures which were suggested to
lead to the delay in clinical action of the commercial tetracaine for-
mulation when applied to the skin.
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